leadf
logo-loader
viewOncimmune

Oncimmune signs up three more US distributors

The agreements will increase the size of the salesforce across the US selling EarlyCDT-Lung to more than 140

Heat diagram of lung
Omncimmune now has seven US distributors for its lung cancer test

Recent Aim new issue Oncimmune Holdings PLC (LON:ONC) has signed up three new US distributors for its early stage lung cancer test. 

The agreements will increase the total salesforce across the US selling EarlyCDT-Lung to more than 140 through seven distributors.

All major US markets are now covered said the company, though discussions are also underway with several other distributors.

 Geoffrey Hamilton-Fairley, Oncimmune’s chief executive, added: "More than 140,000 EarlyCDT-Lung tests have been sold in the US since we began commercialisation in 2012.

 “Our near term strategy in this market is to partner with more distributors and move towards total coverage across the US.” 

EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer.

Oncimmune floated at 130p a share last week. 

Quick facts: Oncimmune

Price: 142.5 GBX

AIM:ONC
Market: AIM
Market Cap: £90.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read